UJAN Breaks Through to New 52-Week High: Amid Mixed Fund Flows
Generated by AI AgentAinvest ETF Movers RadarReviewed byDavid Feng
Tuesday, Dec 2, 2025 3:08 pm ET1min read
Innovator U.S. Equity Ultra Buffer ETF - January Hits 52-Week High Amid Mixed Fund Flows
The Innovator U.S. Equity Ultra Buffer ETF - January (UJAN.B) is an actively managed equity fund designed to provide buffered losses and capped gains on the S&P 500 index over a specific holding period. With an expense ratio of 0.79% and a 1x leverage ratio, the ETF offers a long-only exposure strategy. Recent fund flow data shows a net inflow of $9,002.63 through regular orders on November 28, 2025. However, large institutional orders revealed contrasting movements: block order net outflows
Expert analysis and key market insights keeping you informed on latest trends and opportunities in ETF's.
Latest Articles
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue



Comments
No comments yet